Tebentafusp: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and G-BA (Germany), among others, recommended or restricted tebentafusp, while DMC (Denmark) and NYE METODER (Norway) did not recommend it.
The record spans 4.3 years, opening at AWMSG (Wales) on 24 Mar 2022 and running to 13 Jul 2026.
CIPM (Spain) changed its position: not recommended on 11 May 2023, recommended by 29 Jan 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 13 of 14 records date from 2023 or later.
4 distinct indication wordings are recorded for tebentafusp by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tebentafusp, on 24 Mar 2022; SMC (Scotland) did not open a file until 13 Jul 2026 — a wide spread of 4.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
2 of the 12 agencies here assessed tebentafusp more than once, CIPM (Spain) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
tebentafusp has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tebentafusp reads 7 recommended, 4 not recommended, 2 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 7 May 2026 | programu lekowego B.163.FM. „Leczenie chorych na czerniaka błony naczyniowej oka (ICD-10: C69, C69.3, C69.4) | recommended conditionally | source |
| DMC (Denmark) | 25 Mar 2026 | HLA-A*02:01-positive voksne patienter med ikke-resektabel eller metastatisk uvealt melanom | Ikke anbefalet | source |
| NICE (England) | 9 Jan 2025 | NICE TA1027 | recommended (optimised) | source |
| NYE METODER (Norway) | 8 Dec 2024 | Monoterapi til behandling av humant leukocyttantigen (HLA)-A*02:01-positive voksne pasienter med ikke-resektabelt eller … | not introduced | source |
| ZIN (Netherlands) | 29 Aug 2024 | Advies - vergoed tebentafusp (Kimmtrak®) voor de behandeling van oogkanker | reimbursed | source |
9 further decisions for tebentafusp, across 7 agencies, are not shown here. They include the most recent record on file, 13 Jul 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 14 decisions for tebentafusp from 12 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.